The consistency of bioregulator action across mammalian species is one of the discipline's strongest empirical foundations.
The conservation of short peptide bioregulator action across mammalian species — from rodent to bovine to primate to human — demonstrates that the regulatory mechanism is fundamental to mammalian biology rather than incidental to a single model organism.
This conservation is the empirical basis for translation to human clinical use, and the foundation for cross-indication therapeutic applications across neurological, immune, vascular, longevity, and metabolic domains.
Foundational rodent models established the in-vivo gene-regulatory action of short peptide bioregulators across pineal, thymic, vascular, and hepatic systems. Long-term-administration studies demonstrated lifespan extension and the reversal of age-associated gene-expression patterns.
Vascular and ocular bioregulator studies in rabbit models confirmed tissue-specificity and demonstrated therapeutic efficacy in vascular endothelial dysfunction, retinal degeneration, and post-surgical recovery indications.
Primate models confirmed translational relevance across cognitive, immune, and longevity-associated phenotypes. The conservation of regulatory peptide sequences and the conservation of bioregulator response across primate and rodent models is a key support for clinical translation.
Bovine reproductive studies demonstrated bioregulator action in oocyte maturation and early embryonic development — supporting both veterinary applications and the conservation of the regulatory mechanism across mammalian reproductive biology.
Clinical observation across multiple decades — primarily through institutional research programs in Russia and Eastern Europe — established the safety and indication-specific efficacy of bioregulator preparations across neurological, immune, vascular, longevity, and metabolic indication areas.